Featured Research

from universities, journals, and other organizations

New target identified for preventing bone destruction, such as in arthritis, cancer

Date:
December 4, 2013
Source:
University of Western Ontario
Summary:
A new paper published announces the characterization of a new potent and selective PI3Kdelta inhibitor, GS-9820. The discovery suggests that selective inhibition of PI3K isoforms offers a new approach for the treatment of inflammatory bone diseases and skeletal metastases.

A scanning electron micrograph of ivory surface shows resorption pits where an osteoclast has resorbed the mineralized matrix. Micrograph taken by Western University research technician Tom Chrones at the Biotron Experimental Climate Change Research Centre at Western.
Credit: Western University

The skeleton is constantly being remodelled by the breakdown of old bone by cells called osteoclasts and the formation of new bone by cells called osteoblasts. This coordinated activity is essential for maintaining healthy bone. However, excessive osteoclast activity leads to bone destruction in skeletal diseases such as osteoporosis, rheumatoid arthritis and cancer metastases in bone. A family of signaling enzymes known as phosphatidylinositol 3-kinases (PI3Ks) control diverse cell functions but, up until now, little was known about the function of specific PI3K isoforms in osteoclasts.

A paper published in the December 6 issue of The Journal of Biological Chemistry announces the characterization of a new potent and selective PI3Kdelta inhibitor, GS-9820. The discovery was made by members of Western University's Bone and Joint Initiative with collaborators from Nihon University, the University of Calgary and Gilead Sciences, Inc.

Graduate student Ryan Shugg, working under the supervision of Stephen Sims, PhD, and Jeff Dixon, PhD, of Western's Department of Physiology and Pharmacology, used a panel of isoform-selective inhibitors and found that one isoform in particular, PI3Kdelta, regulates osteoclast shape and resorptive activity.

Sims says, "These findings suggest that selective inhibition of PI3K isoforms offers a new approach for the treatment of inflammatory bone diseases and skeletal metastases."

The studies were carried out by an interdisciplinary team, which included undergraduate student Ashley Thomson, visiting professor Natsuko Tanabe, research scientist Alexey Pereverzev, investigator Frank Jirik at the McCaig Institute for Bone and Joint Health (University of Calgary), along with researchers Adam Kashishian, Bart Steiner, Kamal Puri, and Brian Lannutti from Gilead Sciences.

"Collaboration among researchers at Gilead Sciences, Western, Calgary and Nihon Universities was critical for accessing and testing this novel inhibitor" says Sims. "Such partnerships are essential for translating progress in fundamental cell biology into therapeutic advances."


Story Source:

The above story is based on materials provided by University of Western Ontario. Note: Materials may be edited for content and length.


Journal Reference:

  1. Shugg RP, Thomson A, Tanabe N, Kashishian A, Steiner BH, Puri KD, Pereverzev A, Lannutti BJ, Jirik FR, Dixon SJ, Sims SM. Effects of Isoform-Selective Phosphatidylinositol 3-Kinase Inhibitors on Osteoclasts: ACTIONS ON CYTOSKELETAL ORGANIZATION, SURVIVAL AND RESORPTION. J Biol Chem., October 2013

Cite This Page:

University of Western Ontario. "New target identified for preventing bone destruction, such as in arthritis, cancer." ScienceDaily. ScienceDaily, 4 December 2013. <www.sciencedaily.com/releases/2013/12/131204130954.htm>.
University of Western Ontario. (2013, December 4). New target identified for preventing bone destruction, such as in arthritis, cancer. ScienceDaily. Retrieved September 3, 2014 from www.sciencedaily.com/releases/2013/12/131204130954.htm
University of Western Ontario. "New target identified for preventing bone destruction, such as in arthritis, cancer." ScienceDaily. www.sciencedaily.com/releases/2013/12/131204130954.htm (accessed September 3, 2014).

Share This



More Health & Medicine News

Wednesday, September 3, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Snack Attack: Study Says Action Movies Make You Snack More

Snack Attack: Study Says Action Movies Make You Snack More

Newsy (Sep. 2, 2014) You're more likely to gain weight while watching action flicks than you are watching other types of programming, says a new study published in JAMA. Video provided by Newsy
Powered by NewsLook.com
U.N. Says Ebola Travel Restrictions Will Cause Food Shortage

U.N. Says Ebola Travel Restrictions Will Cause Food Shortage

Newsy (Sep. 2, 2014) The U.N. says the problem is two-fold — quarantine zones and travel restrictions are limiting the movement of both people and food. Video provided by Newsy
Powered by NewsLook.com
Doctors Fear They're Losing Battle Against Ebola

Doctors Fear They're Losing Battle Against Ebola

AP (Sep. 2, 2014) As a third American missionary is confirmed to have contracted Ebola in Liberia, doctors on the ground in West Africa fear they're losing the battle against the outbreak. (Sept. 2) Video provided by AP
Powered by NewsLook.com
Tech Giants Bet on 3D Headsets for Gaming, Healthcare

Tech Giants Bet on 3D Headsets for Gaming, Healthcare

AFP (Sep. 2, 2014) When Facebook acquired the virtual reality hardware developer Oculus VR in March for $2 billion, CEO Mark Zuckerberg hailed the firm's technology as "a new communication platform." Duration: 02:24 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins